Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. Hepatol Commun. 2020;4:267–83.

Google Scholar 

Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of non-alcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.

PubMed  Google Scholar 

Eguchi Y, Wong G, Lee EI, et al. Epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: a focused literature review. JGH Open. 2020;4:1035–41.

Google Scholar 

Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67:328–57.

PubMed  Google Scholar 

Yamashita S, Masuda D, Matsuzawa Y. Clinical applications of a novel selective PPARα modulator, pemafibrate, in dyslipidemia and metabolic diseases. J Atheroscler Thromb. 2019;26:389–402.

CAS  PubMed  PubMed Central  Google Scholar 

Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for the treatment of atherogenic dyslipidemia. Cardiovasc Diabetol. 2021;20:111.

Google Scholar 

Seko Y, Yamaguchi K, Umemura A, et al. Effect of pemafibrate on fatty acid levels and liver enzymes in non-alcoholic fatty liver disease patients with dyslipidemia: a single-arm, pilot study. Hepatol Res. 2021;51:64–74.

Google Scholar 

Shinozaki S, Tahara T, Lefor AK, et al. Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study. Clin Exp Hepatol. 2021;7:172–7.

PubMed  PubMed Central  Google Scholar 

Brunt EM, Janney CG, Di Bisceglie AM, et al. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.

CAS  PubMed  Google Scholar 

Matteoni CA, Younossi ZM, Gramlich T, et al. Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.

CAS  PubMed  Google Scholar 

Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–85.

CAS  PubMed  PubMed Central  Google Scholar 

Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with non-alcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165:305–15.

PubMed  Google Scholar 

Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391:299–310.

CAS  PubMed  Google Scholar 

Harrison SA, Bedossa P, Guy CD, et al. Phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497–509.

PubMed  Google Scholar 

Sanyal AJ, Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391:311–9.

CAS  PubMed  Google Scholar 

Newsome PN, Sanyal AJ, Engebretsen KA, et al. Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the Phase 3 ESSENCE trial. Aliment Pharmacol Ther. 2024;60:1525–33.

CAS  PubMed  PubMed Central  Google Scholar 

Akuta N, Watanabe C, Kawamura Y, et al. Effects of a sodium-glucose cotransporter 2 inhibitor in non-alcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies. Hepatol Commun. 2017;1:46–52.

CAS  PubMed  PubMed Central  Google Scholar 

Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088–93.

CAS  PubMed  Google Scholar 

Eguchi A, Yoneda M, et al. Randomised clinical trial: pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2021;54:1263–77.

PubMed  PubMed Central  Google Scholar 

Ikeda S, Sugihara T, Kihara T, et al. Pemafibrate ameliorates liver dysfunction and fatty liver in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a retrospective study with the outcome after a mid-term follow-up. Diagnostics (Basel). 2021;11:2316.

CAS  PubMed  Google Scholar 

Suzuki Y, Maekawa S, Yamashita K, et al. Effect of a combination of pemafibrate and a mild low-carbohydrate diet on obese and non-obese patients with metabolic-associated fatty liver disease. J Gastroenterol Hepatol. 2023;38:921–9.

CAS  PubMed  Google Scholar 

Kikuchi M, Kikuchi M, Konishi M. Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia. Clin Exp Hepatol. 2024;10:182–7.

PubMed  PubMed Central  Google Scholar 

Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1264–81.

PubMed  Google Scholar 

Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1717–30.

PubMed  Google Scholar 

Abildgaard J, Danielsen ER, Dorph E, et al. Ectopic lipid deposition is associated with insulin resistance in postmenopausal women. J Clin Endocrinol Metab. 2018;103:3394–404.

PubMed  Google Scholar 

Clarke JD, Cherrington NJ. Non-alcoholic steatohepatitis in precision medicine: unraveling the factors that contribute to individual variability. Pharmacol Ther. 2015;151:99–106.

CAS  PubMed  PubMed Central  Google Scholar 

Francque S, Verrijken A, Caron S, et al. PPARα gene expression correlates with severity and histological treatment response in NASH. J Hepatol. 2021;75:1024–35.

Google Scholar 

Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in the liver. Hepatology. 2014;59:1493–504.

Google Scholar 

Torok NJ. Dysregulation of redox pathways in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2016;311:G667–74.

PubMed  PubMed Central  Google Scholar